Article Sidebar

PDF
Date Published: 17/03/2023
Abstract Views: 274
Views PDF: 98
DOI: https://doi.org/10.51298/vmj.v524i1A.4629
Issue
Vol. 524 No. 1A (2023)
Section
Các bài báo
How to Cite
Nguyễn, T. H. G. ., Bùi , H. N. ., Lê, V. G. ., Văn, Đình H. ., & Nguyễn, Q. V. . (2023). THE CHANGE IN ANTI-SARS-COV-2 ANTIBODY LEVELS IN PEOPLE OVER 60 YEARS OLD AFTER VACCINCATION WITH ASTRAZENECA AND PFIZER IN HA NOI AND HUNG YEN IN 2021-2022. Vietnam Medical Journal, 524(1A). https://doi.org/10.51298/vmj.v524i1A.4629

THE CHANGE IN ANTI-SARS-COV-2 ANTIBODY LEVELS IN PEOPLE OVER 60 YEARS OLD AFTER VACCINCATION WITH ASTRAZENECA AND PFIZER IN HA NOI AND HUNG YEN IN 2021-2022

Thị Hương Giang Nguyễn1,, Hồng Ngọc Bùi 1, Vĩnh Giang Lê1, Đình Hòa Văn1, Quang Vĩnh Nguyễn2
1 Hanoi medical university
2 National lung hospital

Main Article Content

Abstract

Objectives: To describe the change in anti-SARS-CoV-2 antibody levels in people over 60 years old after vaccination with AstraZeneca and Pfizer in Hanoi and Hung Yen in 2021-2022. Study Design: A longitudinal study. Main results: Anti-SARS-CoV-2 antibody concentrations peaked at 14 days post-vaccination, median 14.8 U/ml (IQR: 6.5-25.3) for subjects vaccinated with AstraZeneca and 118.2 U/ml (IQR: 70.3 – 168.6) for subjects with Pfizer vaccine. In the AstraZeneca vaccine group, the antibody levels of women were higher than that of men, the difference was statistically significant. Both AstraZeneca and Pfizer injection groups had no difference in antibody levels between age groups, background disease status. However, antibody levels were higher in the Pfizer vaccine group than in the AstraZeneca vaccine group. Conclusion: Vaccination against COVID-19 helps the body to produce antibodies against SARS-CoV-2 virus. However, the amount of this antibody varies between subjects, vaccines and changes over time after vaccination.

Article Details

Keywords

Antibody concentration, SARS-CoV-2, AstraZeneca, Pfizer

References

1. Chen X, Chen Z, Azman AS, et al. Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis. The Lancet Global Health. 2021;9(5):e598-e609. doi:10.1016/ S2214-109X(21)00026-7
2. What you need to know about COVID-19 vaccines. Accessed November 1, 2021. https://www.unicef.org/vietnam/stories/what-you-need-know-about-covid-19-vaccines
3. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 2021;397(10269):99-111. doi:10.1016/ S0140-6736(20)32661-1
4. CDC. COVID-19 và sức khỏe của quý vị. Centers for Disease Control and Prevention. Published February 11, 2020. Accessed December 26, 2021. https://vietnamese.cdc.gov/ coronavirus/2019-ncov/your-health/about-covid-19/antibodies.html
5. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467-478. doi:10.1016/S0140-6736(20)31604-4
6. Bước đầu mô tả nồng độ kháng thể kháng Vi rút Sars-CoV-2 sau tiêm vắc-xin phòng COVID-19. Accessed May 9, 2022. https://tapchiyhocvietnam.vn/index.php/vmj/article/view/1219/1070
7. Wei J, Pouwels KB, Stoesser N, et al. Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. Nat Med. Published online February 14, 2022:1-11. doi:10.1038/s41591-022-01721-6